Participants in the study involving the delivery system will receive these substances through a specialized pump. This approach involves intrathecal use, meaning the drugs are placed into the space between the membranes that cover the spinal cord to target pain more directly. During the course of the study, participants will be monitored to assess their quality of life, comfort levels, and how they manage the physical and emotional challenges of their condition.

The study aims to determine if methadone, when combined with current pain medication, is more effective at reducing bone pain than morphine in cancer patients. During the study, participants will receive either methadone or morphine capsules in addition to their regular pain medication. The treatment period lasts for three weeks, during which patients will need to take the study medication orally.

Throughout the study period, patients will record their pain levels and any side effects they experience. The study will also look at how the medications affect daily activities and overall quality of life. Both medications will be given in capsule form, with carefully controlled dosing to ensure patient safety.

The purpose of this research is to evaluate if adding this cannabis extract solution to current pain treatment can improve overall symptom management compared to placebo. The medication being tested is taken by mouth as a liquid solution. Study participants will receive either the cannabis extract or placebo while continuing their regular pain medications.

The study will last 8 weeks, during which participants will be monitored for changes in their symptoms. The research team will assess various aspects of well-being, including sleep quality, appetite, energy levels, and pain intensity. This will help determine how effective the cannabis extract is at relieving multiple symptoms that cancer patients commonly experience.

The purpose of the study is to evaluate how well these medications work when combined with stereotactic radiotherapy in treating vertebral metastases. Participants in the study will receive either Zoledronic Acid or Denosumab along with their radiation therapy. The study will last for up to 12 months, during which time the effects of the treatment will be monitored. This includes assessing the control of pain, the stability of the spine, and the prevention of bone complications. Participants will undergo regular check-ups, including imaging tests like MRI scans, to monitor the progress of their treatment.

The study aims to provide valuable information on the cost-effectiveness and overall benefits of adding these medications to standard radiation therapy for patients with vertebral metastases. By analyzing the outcomes, researchers hope to improve treatment strategies and enhance the quality of life for individuals affected by this condition.

Participants in the study will either continue taking paracetamol or switch to a placebo while still receiving their regular opioid treatment. The study will observe how this change impacts their pain levels and any side effects related to opioid use. The trial will last for a short period, and participants will take the medications in tablet form.

The main goal is to see if stopping paracetamol leads to worse pain control compared to keeping it in the treatment plan. This information will help doctors understand the best way to manage pain for patients with metastatic cancer who are already using strong opioids.